Insulet Unveils Next-Gen Omnipod Algorithm Updates at ADA 2026
Event summary
- Insulet presents new Omnipod algorithm updates at ADA 2026, featuring lower target glucose settings and improved automation.
- STRIVE trial data supports regulatory submission for Omnipod 6 Automated Insulin Delivery System.
- EVOLUTION 3 study evaluates fully closed-loop system for type 2 diabetes patients.
- Company highlights integration with Abbott’s FreeStyle Libre 3 Plus sensor.
- Investor webcast scheduled for June 8, 2026 to recap conference highlights.
The big picture
Insulet’s presentation at ADA 2026 underscores the growing importance of automated insulin delivery systems in diabetes management. The company’s focus on simplifying technology and improving outcomes aligns with broader industry trends toward more user-friendly, effective diabetes care solutions. The success of Omnipod 6 could significantly expand Insulet’s market share in the competitive AID space.
What we're watching
- Regulatory Approval
- Whether Omnipod 6 will gain FDA approval based on STRIVE trial results.
- Market Adoption
- The pace at which type 2 diabetes patients adopt automated insulin delivery systems.
- Competitive Positioning
- How Insulet’s algorithm updates will differentiate it from competitors in the AID space.